<DOC>
	<DOC>NCT02912845</DOC>
	<brief_summary>The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to &lt;17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).</brief_summary>
	<brief_title>Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<criteria>Healthy children (male and female) ages 0 months to &lt;17 years. Have been exposed or possibly exposed to rabies. Are indicated to receive postexposure prophylaxis (PEP) against rabies infection. Have documented informed consent from the child's parent(s) or legal guardian(s) and assent from the child if appropriate. History of previous administration of rabies vaccine or human rabies immune globulin (HRIG) Rabies exposure or possible rabies exposure more than seven days prior to initiation of PEP, or timing of exposure unknown</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>